SecurityXENT / Intersect ENT, Inc. (46071F103)
IndustrySurgical and Medical Instruments and Apparatus
Common Shares Outstanding29,804,937 shares (as of 2017-12-31)
Total Insiders28
Total Directors9
Total Officers9

Stock Insider Trading (from SEC Form 4)

Intersect ENT, Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

XENT / Intersect ENT, Inc. insiders include McKhann Chas FEDERMAN IRWIN, Lucchese Cynthia L, VERNON W ANTHONY, KLEINER PERKINS CAUFIELD & BYERS XI B LP, de Clercq Casper L., and YOUNG PHILIP M, Kaufman Richard E, HILLEMAN JERYL L, U S Venture Partners IX L P, KLEINER PERKINS CAUFIELD & BYERS XI-A LP, Mead Dana G Jr., Tansey Casey M, Lehman David Aaron, Parker Drake R., Presidio Management Group IX, L.L.C., Kline Teresa L., GALLAHUE KIERAN, MOLL FREDERIC H, Wolbeck Amy, KPCB XI Associates, LLC, Matteucci Paul A, Earnhardt Lisa D, Stambaugh James, ROOT JONATHAN D, CARSCADDEN GWEN R., LIDDLE DAVID E, KRAUSZ STEVEN M, .

Insider Roster

Insider Dir Off 10% Shares Owned
Earnhardt Lisa D President and CEO, Director
X X 510,865
HILLEMAN JERYL L Chief Financial Officer
X 23,432
Kaufman Richard E Sr VP& Chief Operating Officer
X 87,512
Lucchese Cynthia L Director
X
Kline Teresa L. Director
X
MOLL FREDERIC H Director
X
Lehman David Aaron General Counsel
X 15,213
CARSCADDEN GWEN R. Chief People Officer
X 9,156
Parker Drake R. Chief Business Officer
X 3,000
Mead Dana G Jr. Director
X 8,242
VERNON W ANTHONY Director
X 2,546
Tansey Casey M Director
X 2,546
GALLAHUE KIERAN Director
X 10,546
Wolbeck Amy V.P. Regulatory Affairs & Qlty
X
Stambaugh James VP Clinical Affairs
X
McKhann Chas Chief Commercial Officer
X
de Clercq Casper L. Director
X
KPCB XI Associates, LLC 10% Owner
KLEINER PERKINS CAUFIELD & BYERS XI-A LP 10% Owner
KLEINER PERKINS CAUFIELD & BYERS XI B LP 10% Owner
X
KRAUSZ STEVEN M 10% Owner
LIDDLE DAVID E 10% Owner
Matteucci Paul A 10% Owner
ROOT JONATHAN D 10% Owner
Presidio Management Group IX, L.L.C. 10% Owner
YOUNG PHILIP M 10% Owner
U S Venture Partners IX L P 10% Owner
FEDERMAN IRWIN 10% Owner
X
KLEINER PERKINS CAUFIELD & BYERS XI-A LP 10% Owner
KPCB XI Associates, LLC 10% Owner
KLEINER PERKINS CAUFIELD & BYERS XI B LP 10% Owner
X
ROOT JONATHAN D 10% Owner
YOUNG PHILIP M 10% Owner
Presidio Management Group IX, L.L.C. 10% Owner
U S Venture Partners IX L P 10% Owner
FEDERMAN IRWIN 10% Owner
KRAUSZ STEVEN M 10% Owner
LIDDLE DAVID E 10% Owner
Matteucci Paul A 10% Owner
X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-05-15 4 Earnhardt Lisa D S X D 39.2163 -15,000 510,865 20,034,235
2018-05-15 4 Earnhardt Lisa D M D 13.05 15,000 525,865
2018-05-03 4 HILLEMAN JERYL L S X D 39.9414 -12,833 23,432 935,907
2018-05-03 4 HILLEMAN JERYL L M D 11.12 12,833 36,265
2018-04-16 4 Earnhardt Lisa D S X D 39.5945 -15,000 510,865 20,227,444
2018-04-16 4 Earnhardt Lisa D M D 13.05 15,000 525,865
2018-04-03 4 HILLEMAN JERYL L S X D 37.6566 -12,833 23,432 882,369
2018-04-03 4 HILLEMAN JERYL L M D 11.12 12,833 36,265
2018-03-15 4 Earnhardt Lisa D S X D 38.3194 -15,000 510,865 19,576,040
2018-03-15 4 Earnhardt Lisa D M D 13.05 15,000 525,865
2018-03-06 4 HILLEMAN JERYL L S X D 35.9207 -12,833 23,432 841,694
2018-03-06 4 HILLEMAN JERYL L M D 11.12 12,833 36,265
2018-02-15 4 Earnhardt Lisa D S X D 36.3959 -15,000 510,865 18,593,391
2018-02-15 4 Earnhardt Lisa D M D 13.05 15,000 525,865
2018-02-06 4 HILLEMAN JERYL L S X D 35.7979 -12,833 12,932 462,938
2018-02-06 4 HILLEMAN JERYL L M D 11.12 12,833 25,765
2018-02-01 4 Kaufman Richard E S X D 37.2106 -958 87,512 3,256,374
2018-01-17 4 Parker Drake R. A D 3,000 3,000
2018-01-17 4 CARSCADDEN GWEN R. A D 5,300 9,156
2018-01-17 4 Kaufman Richard E A D 6,000 88,470
2018-01-17 4 Lehman David Aaron A D 7,500 15,213
2018-01-17 4 HILLEMAN JERYL L A D 10,500 23,432
2018-01-18 4 Earnhardt Lisa D S X D 33.4672 -11,166 510,865 17,097,221
2018-01-17 4 Earnhardt Lisa D A D 25,500 522,031
2018-01-17 4 Kaufman Richard E S X D 32.9796 -25,000 82,470 2,719,828
2018-01-16 4 Kaufman Richard E S X D 33.6865 -25,000 107,470 3,620,288
2018-01-12 4 CARSCADDEN GWEN R. S X D 34.3476 -10,000 3,856 132,444
2018-01-12 4 CARSCADDEN GWEN R. M D 12.19 10,000 13,856
2018-01-11 4 HILLEMAN JERYL L S X D 33.8052 -12,835 12,932 437,169
2018-01-11 4 HILLEMAN JERYL L M D 11.12 12,835 25,767
2018-01-01 4 CARSCADDEN GWEN R. F D 33.9328 -644 3,856
2018-01-01 4 Earnhardt Lisa D F D 33.9328 -6,834 496,531
2018-01-01 4 HILLEMAN JERYL L F D 33.9328 -2,068 12,932
2018-01-01 4 Kaufman Richard E F D 33.9328 -1,287 132,470
2018-01-01 4 Lehman David Aaron F D 33.9328 -1,287 7,713
2017-12-15 4 Earnhardt Lisa D S X D 31.8682 -10,685 503,365 16,041,336
2017-12-15 4 Earnhardt Lisa D M D 1.20 2,000 514,050
2017-12-11 4 Lehman David Aaron S X D 32.75 -36,000 9,000 294,750
2017-12-11 4 Lehman David Aaron M D 18.00 36,000 45,000
2017-12-04 4 HILLEMAN JERYL L S X D 30.0641 -12,833 15,000 450,962
2017-12-04 4 HILLEMAN JERYL L M D 11.12 12,833 27,833
2017-11-20 4 MOLL FREDERIC H S D 28.758 -2,500 239,624 6,891,107
2017-11-17 4 MOLL FREDERIC H S D 28.7415 -5,000 242,124 6,959,007
2017-11-16 4 MOLL FREDERIC H S D 28.7707 -6,700 247,124 7,109,930
2017-11-15 4 Earnhardt Lisa D S X D 27.881 -20,000 512,050 14,276,466
2017-11-15 4 Earnhardt Lisa D M D 1.20 10,000 532,050
2017-11-10 4 MOLL FREDERIC H S D 29.00 -800 253,824 7,360,896
2017-11-06 4 HILLEMAN JERYL L S X D 27.7822 -12,833 15,000 416,733
2017-11-06 4 HILLEMAN JERYL L M D 11.12 12,833 27,833
2017-10-16 4 Earnhardt Lisa D S X D 28.3668 -20,000 522,050 14,808,888
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

Related News Stories

Intersect ENT's (XENT) CEO Lisa Earnhardt on Q1 2018 Results - Earnings Call Transcript

2018-05-02 seekingalpha
Good afternoon, and welcome to the Intersect ENT First Quarter 2018 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After today’s presentation, there will be an opportunity to ask questions. Please note that this event is being recorded. (4-0)

Large Opportunities And High Expectations Battling It Out At Intersect ENT

2018-03-28 seekingalpha
Intersect ENT's products have been shown to reduce inflammation, scarring, and the need for repeat procedures, but not all clinicians are sold on the cost-benefit trade-off. (45-0)

Intersect ENT's (XENT) CEO Lisa Earnhardt on Q4 2017 Results - Earnings Call Transcript

2018-02-28 seekingalpha
Good afternoon, and welcome to the Intersect ENT Fourth Quarter and Year 2017 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After today’s presentation, there will be an opportunity to ask questions. Please note that this event is being recorded.

Intersect ENT (XENT) SINUVA Implant Receives FDA Approval

2017-12-13 zacks
Intersect ENT, Inc. (XENT - Free Report) received approval from the FDA for SINUVA Sinus Implant. The company has been focused on developing innovative therapies for chronic sinusitis patients. (66-0)